A Study of LUCAR-DKS1 in Subjects With Relapsed/Refractory Autoimmune Diseases
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-70
SponsorNanjing Legend Biotech Co.
About this trial
This is a prospective, single-arm, open-label and dose-escalation Investigator Initialed study to evaluate LUCAR-DKS1 in adult subjects with relapsed/refractory autoimmune diseases.
Eligibility criteria
Qualifiers
Subjects voluntary agreement to provide written informed consent.
Aged 18 to 70 years, either sex.
Clinical laboratory values meet screening criteria.
Positive test for CD19 and/ or BCMA
Disqualifiers
Active infections such as hepatitis and tuberculosis.
Other autoimmune diseases.
Serious underlying diseases such as tumor, uncontrolled diabetes.
Female subjects who were pregnant, breastfeeding.
Trial design
Treatments tested in this trial
- LUCAR-DKS1 NK cells
Treatment groups
36 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov